A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma [PDF]
Frontiers in Oncology, 2023 This review aims to summarize the putative role of histone deacetylases (HDACs) in rhabdomyosarcoma (RMS) and the effects of HDAC inhibitors (HDACi) on RMS by elucidating and highlighting known oncogenic pathways, mechanisms of resistance, and the ...
Omar Selim +7 more
doaj +2 more sources
Role of histone deacetylase inhibitors in non-neoplastic diseases [PDF]
HeliyonBackground: Epigenetic dysregulation has been implicated in the development and progression of a variety of human diseases, but epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small molecules ...
Chunxiao Zhou +7 more
doaj +2 more sources
Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives [PDF]
Experimental Hematology & OncologyHistone deacetylase inhibitors (HDACis) are a significant category of pharmaceuticals that have developed in the past two decades to treat multiple myeloma. Four drugs in this category have received approval from the U.S.
Jingjing Pu +6 more
doaj +2 more sources
Histone deacetylase inhibitors for leukemia treatment: current status and future directions [PDF]
European Journal of Medical ResearchLeukemia remains a major therapeutic challenge in clinical oncology. Despite significant advancements in treatment modalities, leukemia remains a significant cause of morbidity and mortality worldwide, as the current conventional therapies are ...
Mohammad-Salar Hosseini +4 more
doaj +2 more sources
Current treatment strategies targeting histone deacetylase inhibitors in acute lymphocytic leukemia: a systematic review [PDF]
Frontiers in OncologyAcute lymphocytic leukemia is a hematological malignancy that primarily affects children. Long-term chemotherapy is effective, but always causes different toxic side effects.
Yingjun Zhang +19 more
doaj +2 more sources
Histone deacetylase inhibitors
Journal of Education, Health and Sport, 2020 The human genome is contained in chromatin, which is a complex macromolecular complex. It is made of DNA, histones and non-histone proteins. The structure of chromatin and the process of its rearrangement regulate the process of transcription, and hence ...
Marzena Baran +2 more
doaj +1 more source
Medicinal chemistry of histone deacetylase inhibitors [PDF]
Arhiv za farmaciju, 2021 Today, we are witnessing an explosion of scientific concepts in cancer chemotherapy. It has been considered for a long time that genetic instability in cancer should be treated with drugs that directly damage the DNA. Understanding the molecular basis of
Ružić Dušan +3 more
doaj +1 more source
Comprehensive suppression of all apoptosis-induced proliferation pathways as a proposed approach to colorectal cancer prevention and therapy. [PDF]
PLoS ONE, 2014 Mutations in the WNT/beta-catenin pathway are present in the majority of all sporadic colorectal cancers (CRCs), and histone deacetylase inhibitors induce apoptosis in CRC cells with such mutations.
Michael Bordonaro +3 more
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020 Ischemia/reperfusion injury is a complex molecular cascade that causes deleterious cellular damage and organ dysfunction. Stroke, sudden cardiac arrest, and acute myocardial infarction are the most common causes of ischemia/reperfusion injury without ...
Zachary Pickell +3 more
doaj +1 more source
Haematologica, 2018 Histone deacetylase inhibitors are promising agents for various T-cell lymphomas, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and adult T-cell lymphoma/leukemia. CCR4 is an important therapeutic target molecule because mogamulizumab,
Akihiro Kitadate +6 more
doaj +1 more source